The cyclophilin inhibitor CRV431 prevents both cyclophilin A-HBx complex formation and HBV replication

Robert T. Foster(Edison Pharmaceuticals (United States)), Philippe Gallay(Scripps Research Institute), Daniel J. Trepanier(Scripps Research Institute), Daren Ure(NAEJA-RGM Pharmaceuticals (Canada))
Journal of Hepatology
January 1, 2017
Cited by 2


Related Papers